Raising Health

AI is making healthcare advice abundant. But what happens when you actually need to act on it? General Medicine CEO TJ Parker argues that the new bottleneck is getting the lab, booking the specialist, filling the prescription, or understanding what any of it will cost. At BUILD 2026, a16z General Partner Vineeta Agarwala sits down with TJ to unpack General Medicine's vision for a healthcare “store”: one place where patients can understand their options, prices, and insurance coverage, then actually get care. They discuss why convenience can materially change patient behavior, how AI can connect medical records and benefits to the right next step, and what TJ learned building PillPack and Amazon Pharmacy about making a complicated healthcare system feel simple.

a16z General Partner Jorge Conde sits down with Moderna CEO Stéphane Bancel to discuss a major milestone for mRNA technology: positive Phase 3 results from Moderna and Merck’s individualized treatment for melanoma, after more than a decade of work on personalized cancer vaccines. Stéphane explains how the treatment works by sequencing an individual patient’s tumor and healthy cells, identifying the mutations most relevant to their cancer, and encoding up to 34 of them into an mRNA designed specifically for that patient. Rather than simply unleashing the immune system, the goal is to teach it exactly what to recognize and attack. They also unpack the engineering challenge of manufacturing a different medicine for every patient, how Moderna has brought the process down to roughly 42 days from biopsy to treatment, and what it would take to manufacture personalized medicines at scale. Finally, Stéphane looks beyond melanoma to lung, kidney, bladder, pancreatic, and gastric cancers, as well as Moderna’s longer-term work applying mRNA to rare genetic and autoimmune diseases.

Julie Yoo sits down with Dr. Suchi Saria, founder and CEO of Bayesian Health, to discuss the current state of clinical AI and what it takes to deploy AI systems in real-world healthcare settings. While much of the recent attention around AI has focused on copilots, chatbots, and administrative workflows, Saria argues that the greatest opportunity lies in helping clinicians make better decisions at the point of care. She explains how Bayesian Health's clinical intelligence platform continuously analyzes multimodal patient data to identify signs of deterioration, sepsis, and other high-risk conditions before they become medical emergencies. The conversation explores FDA approval, reimbursement, clinician trust, AI governance, hospital workflows, and why healthcare requires a higher standard of evidence than most software categories. Along the way, Saria shares lessons from bringing AI into clinical practice, the future of proactive medicine, and why the next era of healthcare may be defined by continuous intelligence rather than reactive care.

Nicolás Abad, founder and CEO of Telepatía, joins a16z to discuss building AI-powered tools for healthcare in Latin America. Inspired by the loss of his father to a preventable medical error, Adbad set out to address one of the region’s most significant challenges: a shortage of doctors, fragmented medical records, and limited healthcare infrastructure across a population of more than 700 million people. Telepatía's first product acts as a clinical copilot, helping physicians document visits, access patient context, and make more informed decisions. The conversation explores healthcare delivery in Latin America, AI-assisted medicine, medical errors, electronic health records, and why Abad believes AI can help expand access to care while improving outcomes. Along the way, he shares his vision for building an “AI doctor for doctors” and the long-term goal of transforming healthcare across the region.

This episode originally aired on StartUp Health. Unity Stoakes speaks with Julie Yoo, general partner at a16z, about why healthcare is poised to benefit more from AI than any other industry, how the business profile of health tech companies has fundamentally shifted, and what founders need to show up with today to stand out at the seed and Series A stages.

Daisy Wolf speaks with Dr. Andrew Huberman, professor of neurobiology and ophthalmology at Stanford University and host of the Huberman Lab podcast. They discuss how the pandemic sparked a consumer health revolution, the emerging peptide and GLP landscape, what the science actually says about focus drugs, and the neurotechnologies Huberman believes will let us write to our own biology within the next five years.

a16z Partners Daisy Wolf and Eva Steinman talk with Zach Cohen and Raymond Wang, cofounders of Ease Health, a company building an AI operating system for behavioral health that combines CRM, EHR, and revenue cycle management into a single platform. They discuss why behavioral health software has lagged behind, what it means to build AI native versus AI integrated, and why Zach left his job as an investor at a16z to go build in this space. They also cover how Ease plans to replace the dozen software vendors most practices rely on today.

At the Oliver Wyman Health Innovation Summit 2025, Julie Yoo, General Partner at a16z Bio + Health, makes the case that healthcare is uniquely positioned to benefit from AI more than any other industry. She argues that healthcare's historical underinvestment in technology is now an asset, enabling the industry to leapfrog directly to AI-native models of care delivery with unprecedented speed and scale.

a16z general partner Julie Yoo talks with Nikhil Buduma, CEO and cofounder of Ambience Healthcare, to discuss how AI is transforming clinical workflows. They cover the early days of deep learning, why Ambience started by running a medical practice before building a platform company, and what it takes to achieve high clinician adoption rates at major academic medical centers. They also dig into the challenge of building products when AI capabilities change every few months, the real ROI that's finally converting CFOs, and why this might be the moment to reimagine the legacy EHR stack.

a16z investors Daisy Wolf and Eva Steinman talk with Bobby Samuels, cofounder and CEO of Protege. They discuss the myth that we've run out of data for AI, how Protege connects healthcare systems and other data holders with the major AI labs, and why real-world data beats synthetic data for training models. Bobby also covers the growing demand for eval datasets, expanding beyond healthcare into video and audio, and what he's seeing from the biggest AI companies as they race to acquire training data.

Recently, a16z Bio + Health general partner Julie Yoo spoke with Nikita Singareddy, cofounder of Fortuna, and Florian Otto, cofounder of Cedar. They talked about why healthcare affordability is reaching a breaking point, how AI voice agents are transforming patient financial experiences, and what it will take to leapfrog decades of administrative burden in Medicaid—from 30-page paper applications to legacy technology systems built in the 1990s to the real opportunity for giving every American a "five-star healthcare experience."

Out-of-Pocket is a healthcare education company founded by Nikhil Krishnan that helps people understand how healthcare works and how to navigate it in practice. In this episode, a16z investing partner Jay Rughani and Nikhil discuss why health insurance is losing its role as the default way people access care. They explain how rising costs are pushing more consumers to pay out of pocket for diagnostics, preventive care, and navigation. The conversation also looks at what this shift means for startups, AI-powered tools, regulation, and access as healthcare continues to move beyond insurance.

Cofounders Jeremy Wohlwend and Gabriele Corso join the a16z podcast to discuss the launch of Boltz, a public benefit company building AI infrastructure for molecular biology. The conversation explains how breakthroughs following AlphaFold moved the field beyond protein structure prediction into modeling biomolecular interactions and binding strength, why open-source Boltz models saw rapid adoption across pharma and biotech, and how that work is now being productized. They outline the launch of Boltz Lab, a platform that brings protein and small-molecule design agents into scientist workflows, Boltz’s decision to operate as an infrastructure company rather than a therapeutics company, and how AI could reduce early drug discovery bottlenecks by improving molecular design and speeding iteration between computation and the lab.

In this episode, a16z GP Julie Yoo sits down with Peter McCanna, CEO of Baylor Scott & White Health, to break down how one of America's largest health systems is transforming from a supply-driven "walled castle" to a customer-centric ecosystem, and how it's achieving a 10% operating margin while most hospitals struggle to stay in the black. They get into why helping his father navigate healthcare convinced Pete the entire system is fundamentally broken, what differentiates academic medical centers from community health systems, and why traditional hospital economics root out essential services like behavioral health. Peter also explains how ambient AI reduced physician burnout rates by 70%, why AI will eventually replace any job involving human-screen interaction, and what he looks for in startup partnerships beyond just TAM and business fundamentals.

A labor and delivery nurse who ran Senate healthcare policy now manages $1.7 trillion in federal health spending—and she runs her team like a startup. Steph Carlton, Chief of Staff and Deputy Administrator at CMS, reveals the OKRs driving Medicare and Medicaid, why they're killing social determinants funding while building consumer health apps at scale, and how real-time provider data could collapse the 18-month lag between care delivery and payment. The team mixing founders with policy veterans is rewriting quality measures around VO2 max and app engagement, not just disease management—because preventing illness years before it happens might finally be worth more than treating it after.

Drug discovery has doubled the flow of candidates, but approvals remain roughly flat. The constraint is development, not discovery. In this episode, a16z General Partner, Jorge Conde talks with Formation Bio cofounder and CEO Ben Liu about building a modern pharma company around clinical execution. They discuss Formation Bio’s hub-and-spoke model for acquiring and advancing assets, how AI compresses trial timelines and costs, picking winners, regulatory strategy, and what it would take to move from about 50 approvals a year to many more. They also touch on global competition and why clinical proof still drives value in today’s market.

Josh Weiner left Meta to return to CVS Health with two painful realizations: consumers don't manage their health—they expect it, and the healthcare market fundamentally violates every principle of economics. In this conversation with a16z's Julie Yoo, the CVS Senior VP explains why 50% of Americans can't afford a healthcare emergency, how CVS is becoming a platform to solve structural healthcare problems, and why the future depends on consumers finally controlling their own health data.

For the first time in human history, we can diagnose thousands of genetic diseases—often for under $1,000—but we still can't treat most of them. The problem isn't understanding what's broken; it's delivering the fix to the right cells. Eric Kelsic, CEO of Dyno Therapeutics, joins a16z's Jorge Conde to explain how AI-designed protein shells are solving gene therapy's delivery crisis. They explore why Huntington's patients can now get 15 extra years of healthy life, how Dyno inverted the liver-to-brain delivery ratio by 1000x, and why capsids evolved by nature are now being designed by machine learning models trained on millions of variants. Eric introduces the concept of genetic agency—humanity's first-ever ability to take action at the DNA level—and details why solving delivery for common diseases will make ultra-rare disease treatments economically viable. Plus: what happens when gene therapy requires neurosurgery today but could be a simple injection tomorrow, why recent deaths in clinical trials prove we need better technology now, and how genetic medicine could become as routine as surgery within our lifetimes.

Cancer care in the U.S. costs over $250 billion each year, and nearly 2 million Americans receive a new diagnosis annually, yet too often the journey begins with silence: no call, no plan, no guide. In this episode, a16z’s Vineeta Agarwala and Jay Rughani talk with Thyme Care leaders Robin Shah (cofounder and CEO), Bobby Green, MD (president and CMO), and Brad Diephuis, MD (president and COO) about rebuilding oncology around the patient. They cover where the system breaks, how navigation plus value-based contracts align incentives, how AI can extend clinicians, and what scale looks like today, more than 83,000 active patients. A concise blueprint for truly patient-centered cancer care.

In this episode, Julie Yoo and Jay Rughani are joined by Thatch cofounders Chris Ellis and Adam Stevenson to explore why ICHRA—a more recent policy innovation—might quietly revolutionize employer-sponsored health benefits.

In this episode, Sprinter Health co-founders Max Cohen and Cameron Behar sit down with Julie Yoo to unpack how their home-based care model reaches underserved populations and reintegrates “the unengaged” into the healthcare system.

In this episode, Tennr cofounder and CEO Trey Holterman sits down with a16z’s David Haber and Jay Rughani to unpack one of healthcare’s most overlooked pain points: patient referral logistics.

Malinka Walaliyadde, cofounder and CEO of AKASA, joins Julie Yoo to unpack how large language models have the potential to transform hospital revenue by automating highly nuanced coding and billing workflows.

What if we stopped trying to cure disease and started preventing it instead? In this episode, Eric Topol joins general partner Vijay Pande to unpack the future of aging, prevention, and precision health—as explored in Eric's new book, Super Agers: An Evidence-Based Approach to Longevity.

Arif Nathoo, cofounder and CEO of Komodo Health, joins Jorge Conde and Jay Rughani of a16z Bio + Health.

Marc Andreessen joins Julie Yoo and Vijay Pande.

Seth Hain, SVP of R&D at Epic, joins a16z Bio + Health general partner Julie Yoo.

Elliot Cohen, cofounder of PillPack, joins Julie Yoo, a16z Bio + Health general partner.

Neil Parikh and Daniel Cahn, cofounders of Slingshot AI, join Julie Yoo, general partner at a16z Bio + Health.

Muthu Alagappan, founder and CEO of Counsel Health, joins Julie Yoo, a16z Bio + Health general partner.

Ankit Jain, CEO and cofounder of Infinitus Systems, Inc, joins Julie Yoo, a16z Bio + Health general partner.

Alexander Saint-Amand, cofounder and CEO of Topography, joins Julie Yoo, a16z Bio + Health general partner.

Rajaie Batniji, MD, PhD, Afia Asamoah, JD, and Sanjay Basu, MD, PhD, cofounders of Waymark, join Vineeta Agarwala, MD, PhD.

Hippocratic AI cofounder and CEO Munjal Shah joins a16z Bio + Health general partner Julie Yoo.

Jeff Margolis, founder of TriZetto, joins Julie Yoo, a16z Bio + Health general partner.

Matt Wilsey, cofounder and CEO of Grace Science, joins Jorge Conde, general partner of a16z Bio + Health.

Carolyn Bertozzi, PhD, Director of Sarafan Stanford ChEM-H and professor at Stanford University, joins Jorge Conde, general partner at a16z Bio + Health.

Sajith Wickramasekara, CEO and cofounder of Benchling, joins a16z Bio + Health partners Jorge Conde and Jay Rughani.

Dan Rosenthal, a provider network expert and an advisory partner for a16z Bio + Health, joins Julie Yoo, Bio + Health general partner.

Chris Ellis, CEO and Adam Stevenson, president, both cofounders of Thatch, join Julie Yoo and Jay Rughani of a16z Bio + Health.

Jonathan Lim, chairman and CEO of Erasca, joins Jorge Conde, general partner at a16z.

Vijay Pande, general partner, and Daisy Wolf, investing partner, join host Steph Smith on this crossover episode of the a16z podcast.

Marta Bralic Kerns, founder and CEO of Pomelo Care, joins Will Shrank, MD, a16z Bio + Health venture partner.

Nikita Singareddy, cofounder and CEO of Fortuna Health, joins Will Shrank, MD, a16z Bio + Health venture partner.

Mark Smith, MD, Clinical Professor of Medicine at UCSF, joins Will Shrank, MD, Bio + Health venture partner.

Vijay Pande, PhD, founding partner of a16z Bio + Health, joins Derrick Harris, host of the AI + a16z podcast.

Casey Means, MD, a Stanford-trained physician, cofounder of Levels, and author of the new book Good Energy, joins Vijay Pande, PhD, founding partner of a16z Bio + Health.

Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb, or BMS, joins Jorge Conde, general partner at a16z.

Michael Crackower, PhD, Chief Scientific Officer of Ventus Therapeutics, and Jason Burch, PhD, join Vineeta Agarwala, MD, PhD, general partner at a16z Bio + Health.

Bowen Liu, PhD, investing partner, and Surya Ganguli, PhD, venture partner, join Vijay Pande, PhD, general partner of a16z Bio + Health.

Bruce Levine, PhD, the Barbara and Edward Netter Professor in Cancer Gene Therapy at the University of Pennsylvania, joins Jorge Conde, general partner, and Ginger Liau, partner at a16z Bio + Health.

Julie Yoo and Vijay Pande, a16z general partners, offer a follow-up to the episode Grand Challenges in Healthcare AI.

John Crowley, President and CEO of Biotechnology Innovation Organization (BIO), joined Jorge Conde, general partner at a16z Bio + Health.

Lawrence Ingrassia, author and journalist, joins Vineeta Agarwala, general partner, and Kris Tatiossian, editorial lead at a16z Bio + Health.

Jonathan Swerdlin, cofounder and CEO, and Mark Hyman, MD, cofounder and Chief Medical Officer of Function Health join Vijay Pande, general partner, and Daisy Wolf, investment partner of a16z Bio + Health.

Jonathan Bush, founder and CEO of Zus Health, and Chris Severn, cofounder and CEO of Turquoise Health, join Julie Yoo, general partner, and Colin Rom, head of public policy for a16z Bio + Health.

In this episode, originally recorded for the a16z Podcast, host Steph Smith interviews Pushmeet Kohli, DeepMind's VP of Research focused on AI for science. They are joined by a16z Bio + Health founding partner Vijay Pande.

Chronis Manolis, SVP and Chief Pharmacy Officer of UPMC Health Plan, joins Julie Yoo, general partner, Daisy Wolf, investment partner, and Will Shrank, venture partner, of a16z Bio + Health.

Brooke Boyarsky Pratt, founder and CEO of knownwell, joins Vineeta Agarwala, general partner at a16z Bio + Health.

Carolyn Jasik, MD, Chief Medical Officer of Omada Health, joins Vijay Pande, founding partner of a16z Bio + Health.

Vineeta Agarwala, MD, PhD, joins Luke Timmerman's The Long Run podcast on stage at the Life Science Innovation Northwest Conference.

Kim Branson, PhD, SVP and Global Head of AI and Machine Learning for GSK, joins Vijay Pande, founding partner at a16z Bio + Health.

In this episode, Carl June, MD, pioneering immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.

Tom Hale, CEO of ŌURA, joins Vijay Pande, founding partner, and Daisy Wolf, investment partner at a16z Bio + Health.

Philip Tagari, Chief Scientific Officer of insitro, joins Vijay Pande, founding general partner at a16z Bio + Health.

Vijay Pande, founding general partner of a16z Bio + Health, chats with the builders (and siblings) behind Devoted Health, Ed and Todd Park.

Vijay Pande, founding general partner, and Julie Yoo, general partner at a16z Bio + Health, come together to talk through the grand challenges facing healthcare AI today.

Greg Meyers, EVP and Chief Digital and Technology Officer at Bristol Myers Squibb (or BMS), joins a16z Bio + Health general partner Jorge Conde.

This episode features interviews with payor and provider leaders about what they’re seeing and how they’re thinking about AI. Guided by Julie Yoo, general partner, and Jay Rughani, investment partner at a16z Bio + Health, you'll hear from the executives about how they're utilizing AI, the KPIs they use to gauge effectiveness, and what they consider a good partnership.

Vijay Pande, founding general partner at a16z Bio + Health, joins the Software Engineering Daily podcast to talk about innovation in biotech and healthcare, the biotech startup landscape, the impact of AI, and much more.

Rosana Kapeller, CEO of Rome Therapeutics, and Marty Taylor, physician-scientist at Harvard Medical School, join Vineeta Agarwala, general partner, and Bryan Faust, investment partner at a16z Bio + Health.

Vijay Pande, founding partner of a16z Bio + Health, dives deep with a16z Podcast host Steph Smith into the potential of DNA as a data storage mechanism.

Julie Klapstein, founding CEO of Availity, long-time healthcare executive, and a16z Bio + Health's newest advisory partner, joins Julie Yoo, general partner at a16z Bio + Health.

Scribe Therapeutics cofounder and CEO Benjamin Oakes, PhD, joins a16z Bio + Health founding general partner Vijay Pande.

Josh Clemente, cofounder and president of Levels, joins Vijay Pande, founding general partner, and Daisy Wolf, investment partner at a16z Bio + Health.

Former gymnast and current investor Aly Raisman joins general partner Julie Yoo and investment partner Daisy Wolf of a16z Bio + Health.

Max Cohen, cofounder and CEO of Sprinter Health, and Eren Bali, founder and CEO of Carbon Health, join Julie Yoo, general partner at a16z Bio + Health.

In this episode, Joe Grogan, a senior fellow at the Leonard D. Schaeffer Center for Health Policy and Economics and a former senior government official, joins Vijay Pande, founding partner of a16z Bio + Health to discuss all things regulation.

Today's episode features the CEO of Tome Biosciences, Rahul Kakkar, alongside John Finn, CSO of Tome. They are joined by Jorge Conde, general partner at a16z Bio + Health.

Vijay Pande, founding partner of Bio + Health, is joined by Daphne Koller, Andrew Ng, Aviv Regev, and Jakob Uszkoreit.

Bio Eats World is now Raising Health! On this first episode of Raising Health, Sean Duffy, cofounder and CEO of Omada Health, joins Vijay Pande, founding partner of Bio + Health.

Pranav Rajpurkar, PhD, joins Vijay Pande, founding partner of a16z Bio + Health.

Jordi Mata-Fink, PhD, cofounder of Gate Bioscience, joins Vineeta Agarwala and Ben Portney of a16z Bio + Health.

Mario Schlosser, cofounder, former CEO, and current President of Technology at Oscar Health, joins Julie Yoo of Bio + Health.

Miriam Vogel, President and CEO of EqualAI, cohost of the podcast In AI We Trust?, and Chair of the National AI Advisory Committee, joins Vijay Pande of Bio + Health.

Suchi Saria, PhD, founder and CEO of Bayesian Health and a professor at Johns Hopkins University, joins Vijay Pande of Bio and Health.

Fei-Fei Li, PhD, Professor in the Computer Science Department at Stanford University, and Co-Director of Stanford’s Human-Centered AI Institute, joins Bio + Health founding partner Vijay Pande.

Evan Feinberg, PhD, founder and CEO at Genesis Therapeutics, joins Vijay Pande of Bio + Health.

Olga Troyanskaya, a professor in the department of computer science at Princeton and Deputy Director for Genomics at the Flatiron Institute's Center for Computational Biology in NYC, joins Vijay Pande, founding partner of a16z Bio + Health.

Peter Shalek, a Chief Product Officer, currently at Stellar Health and formerly at AbleTo, and Reena Pande, currently a strategic advisor and formerly the Chief Medical Officer of AbleTo, join Julie Yoo and Justin Larkin of a16z Bio + Health.

Surya Ganguli, PhD, an associate professor at Stanford University and a neural dynamics researcher, joins Vijay Pande of Bio + Health.

This episode is live from our recent AI Revolutionaries (AIR) conference. In this episode, Daphne Koller, founder and CEO at insitro and AI expert, chats with Vijay Pande of Bio + Health.

Today's episode features Aviv Regev, PhD, the Head and Executive VP of Genentech Research and Early Development, and founding co-chair of the Human Cell Atlas. She is joined by Vijay Pande of Bio + Health.

Andrew Ng, PhD, a distinguished authority in the field of AI, joins Vijay Pande, founding partner of a16z Bio + Health.

Carl June, MD, an immunologist and oncologist at the University of Pennsylvania, joins Jorge Conde, general partner at a16z Bio + Health.

In this episode, Dan Nomura, a distinguished professor at UC Berkeley, a repeat founder, and our newest advisory partner, joins general partner Jorge Conde and investment partner Becky Pferdehirt.

a16z founding partner Ben Horowitz joins general partner Jorge Conde at Bio + Health's 2023 BUILD summit.

Lloyd B. Minor, the Dean of the Stanford University School of Medicine, joins Vijay Pande, founding partner of a16z Bio + Health.